--- title: "Pre-market hot trades in US stocks: Atlas Critical Minerals up 15.21% pre-market; Sangamo Therap up 10.26% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/274789520.md" description: "Atlas Critical Minerals pre-market up 15.21%; Sangamo Therap pre-market up 10.26%; Park Ha Biological Tech pre-market up 87.55%; eLong Power pre-market up 52.21%; Concorde pre-market up 36.30%" datetime: "2026-02-04T09:42:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274789520.md) - [en](https://longbridge.com/en/news/274789520.md) - [zh-HK](https://longbridge.com/zh-HK/news/274789520.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274789520.md) | [繁體中文](https://longbridge.com/zh-HK/news/274789520.md) # Pre-market hot trades in US stocks: Atlas Critical Minerals up 15.21% pre-market; Sangamo Therap up 10.26% pre-market **Pre-market Hot Trades in US Stocks** Atlas Critical Minerals is up 15.21% in pre-market trading. Based on recent key news: 1. On February 3, Meta Critical Minerals Inc. announced a private placement plan to issue up to 30 million units at a price of CAD 0.20 per unit, expected to raise up to CAD 6 million. This move may enhance the company's financial strength and drive up the stock price. Source: Public Technologies 2. On February 3, US Critical Metals agreed to sell all its interests in the Sheep Creek project for USD 1 million in cash and 500,000 shares of common stock. This transaction may improve the company's financial situation and stimulate stock price growth. Source: Press Release 3. On February 3, the market expressed concerns about the risks and uncertainties of mineral exploration and development activities, which may affect investor confidence. Source: Public Technologies The mineral industry has seen significant capital inflows recently, but risks should be monitored. Sangamo Therap is up 10.26% in pre-market trading. Based on recent key news: 1. On February 3, Sangamo Therapeutics announced a stock issuance of USD 25 million at a price of USD 0.4719 per share, leading to a 19% drop in stock price. A total of 35.2 million shares and pre-purchase warrants were sold, with proceeds intended for working capital and general corporate purposes. Source: Reuters 2. On February 2, Sangamo Therapeutics' Chief Financial Officer Prathyusha Duraibabu was terminated, and Nikunj Jain was appointed as interim Chief Financial Officer. This personnel change may impact the stability of the company's management. Source: SEC Filing 3. On February 3, Sangamo announced details of the Fabry disease registration study at the 2026 World Symposium, emphasizing the importance of the study and potential advancements in treatment. This move may boost market confidence in the company's R&D capabilities. Source: Public Technologies (PUBT) The gene medicine industry has been volatile recently, and investments should be approached with caution. **Top Gainers in Pre-market US Stocks** Park Ha Biological Tech is up 87.55% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. ELPW is up 52.21% in pre-market trading. Based on recent key news: 1. On February 3, Elong Power announced the completion of its latest business transaction, driving up the stock price. The company holds a leading position in high-power battery technology, and the completion of this transaction has enhanced market confidence in its future development 2. On February 3, the company announced a public offering priced at $7.6 million, leading to stock price fluctuations. This move may affect the company's short-term liquidity, attracting market attention. 3. On February 2, Elong Power detailed business risks in SEC filings, increasing uncertainty for investors. Although the company issued disclaimers regarding future statements, market concerns about its risks remain. The volatility in the new energy sector has intensified, necessitating attention to policy changes. Concorde rose 36.30% in pre-market trading. Based on recent key news: 1. On February 3, Concorde International Group Ltd reached a merger agreement with Yoov Group Holding Limited. The merger agreement values Yoov's equity at $600 million, driving a significant increase in Concorde's stock price. Source: Reuters 2. On February 3, Concorde released merger-related information through the SEC's EDGAR system, further confirming the details of the merger and enhancing market confidence. Source: Public Technologies 3. On February 4, the market's positive reaction to the merger news led to a 36.30% increase in Concorde's stock price in pre-market trading. Source: Benzinga The merger agreement drove the stock price up, and the market response was positive ### Related Stocks - [Atlas Critical Minerals Corporation (ATCX.US)](https://longbridge.com/en/quote/ATCX.US.md) - [Sangamo Therapeutics, Inc. (SGMO.US)](https://longbridge.com/en/quote/SGMO.US.md) ## Related News & Research - [Critical Minerals Group Issues 13.3 Million Unquoted Options Expiring 2028](https://longbridge.com/en/news/277534881.md) - [Stillwater Critical Minerals Exhibiting at Booth 2724 and Core Shack 3116B at the PDAC 2026 Convention in Toronto, March 1-4 | PGEZF Stock News](https://longbridge.com/en/news/277233292.md) - [A Blackstone executive made a revealing comment about the state of private credit](https://longbridge.com/en/news/277758116.md) - [BlackRock's target-date funds are about to get riskier. Here's what you need to know.](https://longbridge.com/en/news/277840500.md) - [ILC Critical Minerals Ltd. Does Not Exercise Option to Buy Lepidico Mauritius Ltd. | ILHMF Stock News](https://longbridge.com/en/news/277760045.md)